Cecilia Yeung, MD, FCAP, discusses why the foundations of cancer research are changing and what hematologist can expect to see in the future. “Prior, they’d use a 3+3 strategy in phase 1 trials,” said Dr. Yeung.
For the full article click here: FDA’s Project Optimus aims to transform early cancer research